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Salmonella  
enterica Serovar 
Typhi with CTX-M 
β-Lactamase,  
Germany 
To  the  Editor:  Infection  with 
Salmonella enterica serovar Typhi, the 
causative agent of typhoid fever, is an 
acute systemic illness with a high pro-
portion of illness and deaths, especial-
ly in developing countries. In Europe, 
S. enterica ser. Typhi infections occur 
among  travelers  returning  from  dis-
ease-endemic areas. After emergence 
of multidrug-resistant S. enterica ser. 
Typhi strains that confer resistance to 
chloramphenicol,  trimethoprim,  and 
ampicillin,  quinolones  have  become 
the  primary  drugs  for  treatment  (1). 
Here we report the isolation of CTX-
M–producing S. enterica ser. Typhi in 
Germany.
We isolated S. enterica ser. Typhi 
from blood and feces specimens from 
a 30-year-old Iraqi woman who was 
admitted  to  the  hospital  in  Cologne 
in August 2008. The patient was fe-
brile,  dizzy,  and  had  epigastric  pain 
and  headache. The  symptoms  began 
2 weeks earlier, after she had returned 
from a month-long visit to her rela-
tives  in  Sulaymaniya,  the  capital  of 
As Sulaymaniyah Governorate in the 
northeastern  Iraqi  Kurdistan  region. 
The interview indicated that the same 
symptoms  had  developed  in  other 
family members in Iraq. The patient 
was  treated  successfully  with  mero-
penem (1 g 3×/day) for 2 weeks, and 
no relapse was observed in a follow-
up period of 6 months.
The  isolated  strain  was  identi-
fied as S. enterica ser. Typhi with the 
VITEK2  system  (VITEK2  GN-card; 
bioMérieux,  Brussels,  Belgium)  and 
by slide agglutination with Salmonel-
la  antisera  (SIFIN,  Berlin,  Germany) 
in  accordance  with  the  Kauffmann-
White  scheme.  By  using  Vi-phage 
typing  according  to  the  International 
Federation  for  Enteric  Phage  Typing 
(L.R.  Ward,  pers.  comm.),  the  strain 
was classified as S. enterica ser. Typhi 
Vi-phage type E9. Antimicrobial drug 
susceptibilities  were  determined  ac-
cording to the guidelines of the Clini-
cal Laboratory Standards Institute with 
the VITEK2 AST-N021 card and Etest 
(bioMérieux). The extended-spectrum 
β-lactamase  (ESBL)  phenotype  was 
confirmed with a combined disk diffu-
sion test (MASTDISCS ID, Mast Diag-
nostica GmbH, Germany). PCR and se-
quence analyses were performed with 
universal primers for the ESBL genes 
blaCTX-M, blaTEM, and blaSHV as described 
previously (2). Primer CTX-M-F 5′-G 
TTCGTCTCTTCCAGAATAAGG-3′ 
and  primer  CTX-M-R  5’-CAG-
CACTTTTGCCGTCTAAG-3′  were   
used for sequencing the entire blaCTX-M 
gene. Investigation of the CTX-M en-
vironment was performed with prim-
ers IS26-F (5′-GCCCTGGTAAGCAG 
AGTTTTTG-3′)  and  IS26-CTX-R   
(5′-ACAGCGGCACACTTCCTAA 
C-3′). The presence of plasmid-medi-
ated quinolone resistance genes (qnr) 
was determined by PCR and sequenc-
ing  of  qnrB ( 3),  qnrS  (primer  F,  5′-
CGGCACCACAACTTTTCAC-3′; 
primer  R,  5′-CAACAATACCCAGT 
GCTTCG-3′), and qnrA (primer F, 5′-
ATTTCTCACGCCAGGATTTG-3′; 
primer R, 5′-CGGCAAAGGTTAGGT 
CACAG-3′). In addition, the nucleotide 
sequences of the quinolone resistance-
determining regions of the gyrA, gyrB, 
parC, and parE genes were determined 
as previously described (4). Transfer of 
β-lactam resistance was tested by broth 
mating  assays  with  a  sodium  azide–
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resistant Escherichia coli J53 recipient. 
Selection of transconjugants was per-
formed on Mueller-Hinton agar plates 
that contained sodium azide (200 μg/
mL) and ampicillin (100 μg/mL). We 
isolated the plasmid DNA of donor and 
transconjugants  using  the  QIAGEN 
Plasmid Mini Kit (QIAGEN, Hilden, 
Germany).
Phenotypically,  the  strain  was 
resistant to ampicillin, ampicillin/sul-
bactam, piperacillin, cefotaxime, cef-
tazidime, cefepime, chloramphenicol, 
streptomycin,  trimethoprim/sulfame-
thoxazole, azithromycin, and nalidixic 
acid. A reduced susceptibility to cip-
rofloxacin was detected (MICCIP = 1 
μg/mL). The  isolate  was  susceptible 
to  imipenem,  meropenem,  gentami-
cin, tobramycin, and amikacin. PCR 
and sequence analyses displayed the 
presence  of  blaCTX-M-15,  blaTEM-1  and 
the qnrB2 gene. We found an amino 
acid  substitution  in  gyrA  gene  (83-
Ser→Phe). No mutations were iden-
tified  in  the  gyrB,  parC,  and  parE 
genes. Sequencing of the insertion ele-
ment (IS)26-F/R amplification product 
showed the location of IS26 transpos-
ase A gene (tnpA), followed by a trun-
cated ISEcp1 mobile element upstream 
of the blaCTX-M-15 gene. By conjugation, 
1 plasmid of ≈50 kbp was successfully 
transferred into an E. coli J53 recipient 
(Figure).  PCR-based  replicon  typing 
(5) showed an IncN–related plasmid. 
The E. coli J53 transconjugant medi-
ated resistance to ampicillin, cefotaxi-
me, ceftazidime, cefepime, trimethop-
rim/sulfamethazole, nalidixic acid and 
showed reduced susceptibility to cip-
rofloxacin (MIC = 0.5 μg/mL). Also, 
in  the  transconjugant,  the  blaCTX-M-15 
and  qnrB2  genes  were  identified  by 
PCR.
ESBL-producing  non-Typhi  se-
rotypes of S. enterica are an increas-
ing  problem  worldwide.  In  Europe 
and Asia,  CTX-M-group  ESBLs  are 
prevalent in S. enterica, and in North 
America,  domestically  acquired 
CTX-M ESBLs were recently identi-
fied in S. enterica ser. Typhimurium 
(6). In S. enterica ser. Typhi, reports 
of ESBLs have been rare. The CTX-
M-15 type that we found has been re-
ported only once previously in S. en-
terica ser. Typhi from Indian patients 
hospitalized in Kuwait (7). In addition 
to cephalosporin resistance mediated 
by ESBLs, the reduced susceptibility 
to quinolones in S. enterica is of con-
cern. In the study isolate, this reduced 
susceptibility was due to a known mu-
tation 83-Ser→Phe in gyrA (8) and the 
acquisition of a qnB2 gene. Plasmid-
mediated Qnr determinants have been 
identified  in  S.  enterica  of  different 
non-Typhi serovars (9), whereas in S. 
enterica ser. Typhi, only mutations in 
gyrase and topoisomerase genes lead-
ing to quinolone resistance had been 
observed previously (8).
In our isolate of S. enterica ser. 
Typhi  that  contained  blaCTX-15  and 
qnrB2, resistance to cephalosporins as 
well as the reduced quinolone suscep-
tibility was easily transferable by con-
jugation into E. coli. This occurrence is 
alarming because the dissemination of 
such strains with acquired resistances 
will further limit the therapeutic op-
tions for treatment of typhoid fever.
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Figure.	Plasmids	isolated	from	Salmonella 
enterica serovar	Typhi	and	Escherichia coli 
J53	transconjugant.	Lane	1,	S. enterica	ser.	
Typhi	218/08	(blaCTX-M-15 + blaTEM-1 + qnrB2);	
lane	2,	E. coli	J53	transconjugant	(blaCTX-M-
15 + qnrB2);	lane	M,	plasmid	marker	E. coli 
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Gordonia sputi  
Bacteremia
To the Editor: In November 2007, 
a 69-year-old man with fever was hos-
pitalized  at  the  Northern  Hospital  in 
Marseilles, France. He also had diabe-
tes, high blood pressure, and alcohol 
and tobacco addictions. In September 
2007, he had received a diagnosis of 
laryngeal cancer, which required 2 che-
motherapy treatments through a central 
venous catheter (CVC), the second of 
which he had received 6 days before 
his November visit. Prostatic cancer, 
diagnosed 1.5 years earlier, had been 
treated by radiotherapy. At the time of 
the November admission, he had leu-
kopenia (1.77 × 109 leukocytes/L with 
0.49 × 109 polymorphonuclear cells/L) 
and  an  elevated  C-reactive  protein 
level (151 mg/L). The patient was ad-
mitted  with  a  preliminary  diagnosis 
of  drug-induced  febrile  granulocyto-
sis;  the  origin  of  his  fever  remained 
unclear.  Blood  for  culture  was  first 
collected from a peripheral vein and 
on  the  next  day  was  collected  from 
a peripheral vein and from the CVC. 
Gram-positive rods grew in the aero-
bic bottle from the CVC sample. The 
microorganism was identified by bio-
chemical tests using API Coryne strip 
(bioMérieux,  Marcy-l’Etoile,  France) 
as Rhodococcus spp. (94% similarity). 
The day after hospital admission, the 
patient  was  empirically  treated  with 
intravenous ticarcillin-clavulanate, 5 g 
3×/day; ciprofloxacin, 200 mg 2×/day; 
and  granulocyte  colony–stimulating 
factor.  One  day  later,  fever  resolved 
and the polymorphonuclear cell count 
was within normal limits. Oral antimi-
crobial drug therapy was continued for 
1 week.
Bacterial  identification  of  the 
strain  was  performed  by  16S  rRNA 
sequencing. We obtained a 1,464-bp 
sequence,  which  was  found  to  dif-
fer at only 2 nt positions from that of 
Gordonia  sputi  (GenBank  accession 
no. X80634). We concluded that our 
patient  had  catheter-related  bacter-
emia caused by G. sputi because he 
was  immunocompromised  and  had 
a CVC. We ruled out a contaminant 
because the organism did not belong 
to the normal flora of human skin and 
because fever resolved after treatment 
with antimicrobial drugs.
The genus Gordona was first de-
scribed in 1971, for coryneform bac-
teria isolated from sputum of patients 
with  pulmonary  disease  or  from  soil 
(1). It is a member of the mycolic acid–
containing group consisting of genera 
Corynebacterium,  Dietzia,  Gordonia, 
Mycobacterium, Nocardia, Rhodococ-
cus, and Tsukamurella. The genus has 
been revised several times by rearrange-
ments with the genera Rhodococcus and 
Nocardia, and the name Gordona was 
changed to Gordonia in 1997. The ge-
nus belongs to suborder Corynebacter-
ineae within the order Actinomycetales 
and  currently  contains  27  recognized 
species; only 7 have been described in 
human disease. Species are identified 
by molecular analysis.
Gordonia spp. cause a wide spec-
trum  of  disease  in  humans  (2–10; 
Table).  Neurologic  and  vascular  in-
fections in immunocompromised and 
immunocompetent patients have been 
reported.  Cutaneous  and  respiratory 
infections, otitis externa, osteitis, and 
arthritis have reportedly occurred only 
in immunocompetent patients. Bacte-
ria have most often been isolated from 
blood samples. Bacteremia has started 
from underlying disease such as a se-
questrated lung (4) or acute cholecys-
tis (5) or has been related to coronary 
artery  surgery  (2)  and  frequently  to 
CVCs  (2,3,6).  Catheter  removal  has 
been  recommended  for  treatment  of 
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